Methylprednisolone Acts on Peripheral Blood Mononuclear Cells and Endothelium in Inhibiting Migration Phenomena in Patients With Multiple Sclerosis | Demyelinating Disorders | JAMA Neurology | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.204.201.220. Please contact the publisher to request reinstatement.
1.
Prat  AAl-Asmi  ADuquette  PAntel  JP Lymphocyte migration and multiple sclerosis: relation with disease and therapy.  Ann Neurol.1999;46:253-256.Google Scholar
2.
Elovaara  IUkkonen  MLeppakynnas  M  et al Adhesion molecules in multiple sclerosis.  Arch Neurol.2000;57:546-555.Google Scholar
3.
Mancuso  FFlower  RJPerretti  M Leukocyte transmigration, but not rolling or adhesion, is selectively inhibited by dexamethasone in the hamster post-capillary venule.  J Immunol.1995;155:377-386.Google Scholar
4.
Hoheisel  DNitz  TFranke  H  et al Hydrocortisone reinforces the blood-brain barrier properties in a serum free cell culture system.  Biochem Biophys Res Commun.1998;244:312-316.Google Scholar
5.
Rollins  BJ Chemokines.  Blood.1997;90:909-928.Google Scholar
6.
Sorensen  TLTani  MJensen  J  et al Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients.  J Clin Invest.1999;103:807-815.Google Scholar
7.
Harkness  KAAdamson  PSussman  JD  et al Dexamethasone regulation of matrix metalloproteinase expression in CNS vascular endothelium.  Brain.2000;123(pt 4):698-709.Google Scholar
8.
Burnham  JAWright  RRDreisbach  JMurray  RS The effect of high-dose steroids on MRI gadolinium enhancement in acute demyelinating lesions.  Neurology.1991;41:1349-1354.Google Scholar
9.
Gelati  MCorsini  EDufour  A  et al Reduced adhesion of PBMNCs to endothelium in methylprednisolone-treated MS patients: preliminary results.  Acta Neurol Scand.1997;96:283-292.Google Scholar
10.
Jaffe  EANachman  RLBecker  CGMinic  CR Culture of human endothelial cells derived from umbilical veins: identification by morphologic and immunologic criteria.  J Clin Invest.1973;52:2745-2756.Google Scholar
11.
Kurtzke  JF Rating neurologic impairment in multiple sclerosis: an expanded disability scale (EDSS).  Neurology.1983;33:1444-1445.Google Scholar
12.
Defer  GLBarré  JLedudal  PTillement  JPDegos  JD Methylprednisolone infusion during acute exacerbation of MS: plasma and CSF concentrations.  Eur Neurol.1995;35:143-148.Google Scholar
13.
Pietschmann  PCush  JJLipsky  PEOppenheimer-Marks  N Identification of subsets of human T cells capable of enhanced transendothelial migration.  J Immunol.1992;149:1170-1178.Google Scholar
14.
Ehrilch  LCShuxian  HSheng  WS  et al Cytokine regulation of human microglial cell IL-8 production.  J Immunol.1998;160:1944-1948.Google Scholar
15.
Kossakowska  AEEdwards  DRPrusinkiewicz  C  et al Interleukin-6 regulation of matrix metalloproteinase (MMP-2 and MMP-9) and tissue inhibitor of metalloproteinase (TIMP-1) expression in malignant non-Hodgkin's lymphomas.  Blood.1999;94:2080-2089.Google Scholar
16.
Hofbauer  RFrass  MGmeiner  B  et al Oral contraceptives that contain ethinyl estradiol (0.0035 mg) and cyproterone acetate (2 mg) inhibit leukocyte transmigration through endothelial cell monolayers.  Fertil Steril.1999;72:652-656.Google Scholar
17.
Elovaara  ILalla  MSpare  E  et al Methylprednisolone reduces adhesion molecules in blood and cerebrospinal fluid in patients with MS.  Neurology.1998;51:1703-1708.Google Scholar
18.
Gelati  MCorsini  EDufour  A  et al In vitro effects of high- and low-dose methylprednisolone on HLA-DR, ICAM-1 and VCAM-1 on human microvascular cerebral endothelium.  Can J Neurol Sci.2000;27:241-244.Google Scholar
19.
Baggiolini  M Chemokines and leukocytes traffic.  Nature.1998;392:565-568.Google Scholar
20.
Salmaggi  AGelati  MDufour  A  et al Expression and modulation of interferon gamma inducible chemokines (IP-10, Mig, and I-TAC) in human brain endothelium and astrocytes: possible relevance for the immune invasion of the central nervous system and the pathogenesis of multiple sclerosis.  J Inteferon Cytokine Res. In press. Google Scholar
21.
Iarlori  CReale  MLugaresi  A  et al RANTES production and expression is reduced in relapsing-remitting multiple sclerosis patients treated with interferon-β-1b.  J Neuroimmunol.2000;107:100-107.Google Scholar
22.
Franciotta  DMartino  GZardini  E  et al Serum and CSF levels of MCP-1 and IP-10 in multiple sclerosis patients with acute and stable disease and undergoing immunomodulatory therapies.  J Neuroimmunol.2001;115:192-198.Google Scholar
23.
Stuve  ODooley  NPUhm  JH  et al Interferon β-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9.  Ann Neurol.1996;40:853-863.Google Scholar
24.
Rosenberg  GADencoff  JECorrea Jr  NReiners  MFord  CC Effect of steroids on CSF matrix metalloproteinases in multiple sclerosis: relation to blood-brain-barrier injury.  Neurology.1996;46:1626-1632.Google Scholar
25.
Sellebjerg  FChristensen  MJensen  JFrederiksen  JL Immunological effects of oral high-dose methylprednisolone in acute optic neuritis and multiple sclerosis.  Eur J Neurol.2000;7:281-289.Google Scholar
26.
Gironi  MBergami  ABrambilla  E  et al Immunological markers in multiple sclerosis.  Neurol Sci.2000;21(suppl 2):S871-S875.Google Scholar
27.
Gasperini  CPozzilli  CBastianello  S  et al Effect of steroids on Gd-enhancing lesions before and during recombinant beta interferon 1a treatment in relapsing remitting multiple sclerosis.  Neurology.1998;50:403-406.Google Scholar
Original Contribution
May 2002

Methylprednisolone Acts on Peripheral Blood Mononuclear Cells and Endothelium in Inhibiting Migration Phenomena in Patients With Multiple Sclerosis

Author Affiliations

From the Istituto Nazionale Neurologico "C. Besta," Milan, Italy.

Arch Neurol. 2002;59(5):774-780. doi:10.1001/archneur.59.5.774
Abstract

Background  Intravenous methylprednisolone hemisuccinate is administered to patients with multiple sclerosis (MS) during exacerbations to improve the rate of recovery. Corticosteroids could be beneficial in MS exacerbations also by decreasing transmigration of peripheral blood mononuclear cells (PBMNCs) through the blood-brain barrier.

Objectives  To evaluate how in vivo intravenous methylprednisolone treatment in patients with MS could influence transmigration of PBMNCs in an in vitro model; to perform transmigration experiments through a methylprednisolone-treated endothelium with PBMNCs from untreated healthy control subjects to evaluate putative selective effects of corticosteroids on endothelium; concomitantly, to quantify the concentration of matrix metalloproteinases 2 and 9 in supernatants of PBMNCs and in serum samples from methylprednisolone-treated patients with MS; to evaluate monokine induced by interferon-γ release in the supernatants of human umbilical vein endothelial cells treated with interferon-γ alone or interferon-γ and methylprednisolone; and to perform gene expression studies of matrix metalloproteinases 2 and 9 in human umbilical vein endothelial cells and PBMNCs from methylprednisolone-treated patients with MS.

Patients  Eight patients with MS in exacerbation were studied before and 3 and 24 hours after intravenous methylprednisolone treatment, 1 g.

Results  The absolute number of transmigrated PBMNCs from methylprednisolone-treated patients with MS significantly (P<.01) decreased at 3 hours and increased again at 24 hours, reaching values higher than those before treatment onset. Methylprednisolone was also able to significantly (P<.03) reduce the number of PBMNCs from healthy controls migrating through interferon-γ–stimulated or unstimulated endothelium. In vitro methylprednisolone treatment decreased monokine induced by interferon-γ production in human umbilical vein endothelial cells.

Conclusions  Methylprednisolone may be able to decrease transmigration of PBMNCs through the blood-brain barrier, exerting its inhibitory effects on PBMNCs and endothelium. A "rebound" of transmigration at 24 hours suggests that a single infusion is not optimal for achieving a persistent reduction in transmigration.

×